患者报告结局作为临床试验招募策略的应用
该随机子研究在多中心三级癌症中心开展,纳入接受放疗的乳腺癌患者,评估基于电子患者报告结局(ePRO)提示的招募策略是否与临床试验入组增加相关。结果显示,门户消息组入组率高于标准治疗组,且来自转诊服务的消息回复率高于放疗肿瘤科团队,但入组无显著差异。
要点
- 常规收集的ePRO用于筛查中重度疲劳并主动发送门户消息邀请,与医生转诊相比与更高的试验入组相关。
- 门户消息组回复率35%、入组率20%,标准治疗组转诊率0.5%、入组0例(P < .001)。
- 来自转诊服务的消息回复率44%高于放疗肿瘤科团队的26%(P = .01),但入组无显著差异。
核心结论
- 研究结果提示,使用常规诊疗中的ePRO与症状干预试验的入组增加相关,优于医生转诊。
- 来自转诊服务的直接消息可能支持入组,并有助于减少肿瘤医生层面对于症状干预试验入组的障碍。
研究设计与样本
- 随机子研究,于2022年9月至2023年3月在一家多中心三级癌症中心开展,作为一项正在进行的癌症相关疲劳症状干预临床试验的一部分。
- 纳入在研究期间完成至少1份ePRO问卷的接受放疗的乳腺癌患者。
- 采用医生层面的整群随机化,将符合疲劳条件的患者分配至接受症状干预试验的门户消息邀请或标准治疗(SOC;基于医生的转诊)。
- 每间隔一位患者接受来自主要放疗肿瘤科团队或转诊服务的消息,以评估门户消息来源与回复及入组的关系。
主要发现
- 共1041例患者完成ePRO问卷,其中394例(38%;53例亚洲人[13.6%]、43例黑人[11.0%]、29例西班牙裔[7.4%]、262例白人[66.5%];中位[IQR]年龄55[47-65]岁)在治疗期间报告中度或以上疲劳。
- 210例患者(53.3%)被分配至门户消息组,184例(46.7%)分配至标准治疗组。
- 门户消息组中73例(35%)回复,41例(20%)入组;标准治疗组中1例(0.5%)转诊,0例入组(P < .001)。
- 门户消息回复率转诊服务组为44%,主要放疗肿瘤科服务组为26%(P = .01),但入组无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical trials are critical for progress in oncology; however, only 5% of the adult cancer population participates. Harnessing data that are routinely collected (ie, electronic patient-reported outcomes [ePROs]) may serve as a method to promote trial enrollment. OBJECTIVE: To evaluate if an ePRO-prompted recruitment strategy is associated with increased clinical trial enrollment. DESIGN, SETTING, AND PARTICIPANTS: A randomized substudy was conducted from September 2022 to March 2023 at a multisite tertiary cancer center as part of an ongoing clinical trial that was testing a symptom-intervention for cancer-related fatigue. Patients with breast cancer who were undergoing radiotherapy who completed at least 1 ePRO questionnaire during the study period were included. Physician-level cluster randomization assigned fatigue-eligible patients to either receive a portal message invitation to a symptom-intervention trial or standard of care (SOC; physician-based referral). EXPOSURE: ePRO questionnaires distributed in routine practice were queried weekly and screened for moderate or greater fatigue, the principle inclusion criterion for the primary trial. To assess the association of the portal message source with response and enrollment, every other patient received a message from the primary radiation oncology team or the referral service. MAIN OUTCOMES AND MEASURES: Clinical trial response/referral and enrollment. RESULTS: A total of 1041 patients completed ePRO questionnaires, of whom 394 (38%; 53 Asian [13.6%], 43 Black [11.0%], 29 Hispanic [7.4%], and 262 White individuals [66.5%]; median [IQR] age, 55 [47-65] years) endorsed moderate or greater fatigue while receiving treatment. A total of 210 patients (53.3%) were assigned to receive a portal message and 184 (46.7%) patients, SOC. In the portal message group, 73 patients (35%) responded and 41 (20%) enrolled compared with 1 patient (0.5%) referred and 0 enrolled in the SOC group (P < .001). The response rate to portal messages favored the referral service vs the primary radiation oncology service (44% vs 26%; P = .01), but there was no significant difference in enrollments. CONCLUSIONS AND RELEVANCE: The study results suggest that use of routine care ePROs was associated with greater enrollment in a symptom-intervention trial compared with physician-based referral. Messaging directly from the referral service may support enrollment and help reduce oncology physician-level barriers to trial enrollment for studies testing symptom interventions.
引用
- Verdini NP, Bryl KL, Baser RE, et al. Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment. JAMA Oncol. 2024. PMID: 38602690. doi:10.1001/jamaoncol.2024.0280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。